$CAPR REVIEWING CORP UPDATE
$CAPR Press Release: Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Today 4:01 PM ET (Dow Jones)Print
Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Exosome Platform for COVID-19
-Novel Multivalent Exosome mRNA and VLP Vaccine Candidates Underway in Animal Studies-
-Preclinical Data Shows Positive Antibody Response-
CAP-1002 for COVID-19
-Expanded Access Emergency Use Series Published in Peer Reviewed Journal-
-Randomized, Double-Blind, Placebo-Controlled, Phase II IND Submitted to FDA-
-Plan to Initiate Study in Third Quarter, Subject to FDA Approval-
Duchenne Muscular Dystrophy Program
-Reported Positive Top-Line 12-month Results from HOPE-2 Study-
-In Discussions with FDA on Next Steps in Pathway Forward-
-To Host Conference Call and Webcast Today at 4:30 p.m. ET-
LOS ANGELES, Aug. 06, 2020 (GLOBE NEWSWIRE) --
Capricor Therapeutics ("Capricor") (NASDAQ: CAPR),
a clinical-stage biotechnology company focused on the development of
first-in-class cell and exosome-based therapeutics for the treatment
and prevention of diseases, announced today its financial results for the second quarter ending June 30, 2020 and provided a corporate update.
"We had a very successful first half of 2020,
marked by continued achievements in our expanding cell and exosome programs.
We are now well underway in animal studies and have seen promising results showing the mRNA vaccine is capable of generating an antibody response to multiple antigens expressed by COVID-19.
Two distinct vaccines are now in development,
one using the exosomes as virus-like particles and the other using exosomes loaded with viral protein mRNAs.
We are moving forward as quickly as possible with the goal of bringing
a vaccine into the clinic."
"Additionally, we have submitted a new investigational new drug application (IND) to the FDA for a randomized, placebo-controlled, double-blind,
Phase II clinical trial to treat up to 60 patients in severe or critical condition with COVID-19 with CAP-1002.
Furthermore, we continue to discuss next steps in our DMD program
with the FDA" said Linda Marbán, Ph.D., Capricor's president and chief executive officer.
Dr. Marbán continued,
"We are enthusiastic and encouraged to be engaged in the development of the next generation of potential vaccines using our proprietary exosome platform.
Exosomes are intercellular communicators and are uniquely suited and have the potential to change how we treat,
immunomodulate, and
mediate serious life-threatening illnesses,
correct genetic disorders,
engineer vaccines to prevent diseases,
and modify enzymes.
A key advantage of exosomes beyond the ability to modify cells is the ability to deliver therapeutic payloads, without degradation into specific locations."
Capricor remains diligently focused on the treatment of DMD using CAP-1002.
The FDA has continued to encourage us to conduct a Phase III study, however at this time,
we are still discussing the pathway forward for this program with the FDA.
Once the regulatory pathway is finalized we expect to expand our efforts to seek partnerships for this program.
We also recently participated in the Parent Project Muscular Dystrophy (PPMD)
Virtual Annual Conference to help better inform families and caregivers around the treatment of DMD.
"We are proud to deliver an update of those accomplishments today focused on our exosome platform, COVID-19 and DMD programs and our anticipated milestones in 2020," added Dr. Marbán.
Second Quarter Highlights and Recent Developments
Exosome Platform for COVID-19
AI
